Integra (IART) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Integra LifeSciences reported revenue of $434.93 million for the quarter ended December 2025, reflecting a decrease of 1.7% year-over-year, with EPS at $0.83 compared to $0.97 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $434.35 million by 0.13%, while the EPS surpassed the consensus estimate of $0.79 by 4.73% [1] Revenue Performance - Organic revenue growth was reported at -2.5%, better than the three-analyst average estimate of -3.5% [4] - Codman Specialty Surgical revenue totaled $323.31 million, exceeding the average estimate of $306.21 million by two analysts, representing a year-over-year increase of 2.8% [4] - Tissue Technologies - Private Label revenue was $31.64 million, surpassing the average estimate of $24.41 million, marking a year-over-year growth of 19.6% [4] - Tissue Technologies - Wound Reconstruction and Care revenue was $79.98 million, below the average estimate of $99.43 million, indicating a year-over-year decline of 21.2% [4] - Total revenue for Tissue Technologies was $111.62 million, falling short of the average estimate of $123.85 million, reflecting a year-over-year decrease of 12.8% [4] Stock Performance - Shares of Integra have returned +6.5% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]